
|Videos|March 22, 2017
A Study of Olaparib and Cediranib in Ovarian Cancer
Author(s)Christina M. Annunziata, MD, PhD
Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
FDA Approves SimpleScreen Blood Test for CRC Screening
3
Monthly IVIG Lowers Recurrent Infection Rates in Patients With CLL
4
Dato-DXd Plus Pembrolizumab Elicits Responses Even With Low PD-L1
5


























